Trade Report: Today, JMP Securities Reiterates Buy Rating for Arbutus Biopharma Corp. (ABUS)

Today, JMP Securities Reiterates Buy Rating for Arbutus Biopharma Corp. (ABUS)

Arbutus Biopharma Corp. (NASDAQ:ABUS)‘s stock had its “buy” rating restated by equities research analysts at JMP Securities in a report released on Sunday.

Several other research analysts have also commented on the company. Zacks Investment Research raised Arbutus Biopharma Corp. from a “sell” rating to a “hold” rating in a research report on Thursday, August 18th. William Blair reissued an “outperform” rating on shares of Arbutus Biopharma Corp. in a research report on Sunday, August 21st. Wedbush reissued an “outperform” rating and issued a $20.00 price objective on shares of Arbutus Biopharma Corp. in a research report on Wednesday, July 20th. Leerink Swann reissued a “buy” rating on shares of Arbutus Biopharma Corp. in a research report on Wednesday, July 20th. Finally, Chardan Capital raised Arbutus Biopharma Corp. from a “sell” rating to a “neutral” rating and set a $3.00 price objective on the stock in a research report on Friday, October 14th. They noted that the move was a valuation call. Two research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $7.21.

Arbutus Biopharma Corp. (NASDAQ:ABUS) traded down 1.85% during mid-day trading on Friday, reaching $2.65. The company’s stock had a trading volume of 60,216 shares. The firm has a 50-day moving average of $2.97 and a 200-day moving average of $3.63. Arbutus Biopharma Corp. has a 52 week low of $2.45 and a 52 week high of $5.79. The stock’s market capitalization is $145.33 million.

Several hedge funds have recently made changes to their positions in ABUS. Bank of Montreal Can acquired a new stake in shares of Arbutus Biopharma Corp. during the second quarter worth about $2,822,000. I.G. Investment Management LTD. acquired a new stake in shares of Arbutus Biopharma Corp. during the second quarter worth about $870,000. Suffolk Capital Management LLC raised its stake in shares of Arbutus Biopharma Corp. by 7.6% in the second quarter. Suffolk Capital Management LLC now owns 441,915 shares of the biopharmaceutical company’s stock worth $1,538,000 after buying an additional 31,023 shares during the last quarter. AXA raised its stake in shares of Arbutus Biopharma Corp. by 1.4% in the second quarter. AXA now owns 792,358 shares of the biopharmaceutical company’s stock worth $2,757,000 after buying an additional 11,062 shares during the last quarter. Finally, K2 Principal Fund L.P. raised its stake in shares of Arbutus Biopharma Corp. by 113.6% in the second quarter. K2 Principal Fund L.P. now owns 63,550 shares of the biopharmaceutical company’s stock worth $221,000 after buying an additional 33,796 shares during the last quarter. 31.59% of the stock is currently owned by institutional investors and hedge funds.

Arbutus Biopharma Corp. Company Profile

Related posts

Leave a Comment